Status:
COMPLETED
BIOFLOW-III Canada Satellite Registry
Lead Sponsor:
Biotronik Canada Inc
Conditions:
Coronary Artery Disease
Myocardial Ischemia
Eligibility:
All Genders
18+ years
Brief Summary
For the majority of Coronary Artery Disease (CAD), treatment with Percutaneous Transluminal Coronary Angioplasty (PTCA) provides high initial procedural success. However, the medium to long-term compl...
Eligibility Criteria
Inclusion
- Symptomatic coronary artery disease or documented silent ischemia
- Subject informed consent for data release
- Subject is geographically stable and willing to participate at all follow ups assessments
Exclusion
- Subject did not sign informed consent for data release
- Pregnancy
- Known intolerance to aspirin, clopidogrel, ticlopidine, heparin or any other anticoagulation/antiplatelet therapy required for PCI, stainless steel, sirolimus
- Planned surgery within 6 months of PCI unless dual antiplatelet therapy will be maintained
Key Trial Info
Start Date :
May 13 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2017
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT01880242
Start Date
May 13 2014
End Date
August 1 2017
Last Update
September 21 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada, H2W 1T8
2
St. Michael's Hospital
Toronto, Canada, M5B1WG8